Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

3.340 +0.480 (+16.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Agenus (AGEN) Q1 2023 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
From Agenus
Via Business Wire
Agenus (NASDAQ: AGEN) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer
Via Benzinga
Why Agenus Stock Is Slumping This Week
The biotech may have to raise capital soon. 
Via The Motley Fool
Agenus (AGEN) Q4 2022 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
From Agenus
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
From Agenus
Via Business Wire
Agenus to Participate in May Investor Conferences
From Agenus
Via Business Wire
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
Earnings Preview For Agenus
Via Benzinga
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
From Agenus Inc.
Via Business Wire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
Macro headwinds are weighing on risk-laden biotech stocks today. 
Via The Motley Fool
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
From Agenus Inc.
Via Business Wire
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
From Agenus Inc.
Via GlobeNewswire
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
Conference Call Cancelled 
From Agenus Inc.
Via GlobeNewswire
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET 
From Agenus Inc.
Via GlobeNewswire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET 
From Agenus Inc.
Via GlobeNewswire
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
From Agenus Inc.
Via GlobeNewswire
Agenus to Participate in February Investor Conferences
From Agenus Inc.
Via GlobeNewswire
Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate
Via Benzinga
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Agenus Inc.
Via GlobeNewswire
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
From Agenus Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
From Agenus Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.